AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03819296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy
Study NCT03819296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT
Study NCT03819296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Given intravenously (IV)
Study NCT03819296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Ancillary studies
Study NCT03819296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally
Study NCT03819296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Given IV
Study NCT05489068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing at Intake (MII)
Description: The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.
Study NCT05489068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intake as Usual (IAU)
Description: In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.
Study NCT06222411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluate the impact of organizational interventions for physician development on wellbeing
Description: There is an increasing demand for healthcare organizations and hospitals to address factors contributing to stress and burnout as well as provide effective solutions at an organizational level
Study NCT04992169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-App Parent Training in Pivotal Response Treatment
Description: Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
Study NCT04788992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
Study NCT04788992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
Study NCT04949230 — intervention group
Intervention type: OTHER
Intervention: No Intervention Used
Description: There is no intervention in this study
Study NCT06475690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological interventions
Description: Psychological interventions is used for intervention group
Study NCT06302673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laserpuncture
Description: Laserpuncture : using RJ Laser with Nogier B wave setting, frequency 584 Hz, power 50 mW, wavelength 785 nm, and energy of 2 Joules at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan)
Study NCT05457270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
Study NCT06346977 — intervention group
Intervention type: DRUG
Intervention: Pemetrexed
Description: Intrathecal injection of pemetrexed
Study NCT06302673 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laserpuncture
Description: Sham Laserpuncture: The laser is turned on but not activated at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan).
Study NCT05360810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wei Nasal Jet Tube
Description: comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures~airway devices which can use for gastrointestinal procedures
Study NCT05360810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastro Laryngeal Tube
Description: comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
Study NCT05029037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High doses of intravenous vitamin C
Description: Two (2) High doses of intravenous vitamin C for seven (7) days.
Study NCT05029037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 500 mL
Description: Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days.
Study NCT05656651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise training
Description: Endurance training adapted to age, resting heart rate
Study NCT05656651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval exercise training
Description: Endurance training adapted to age, resting heart rate
Study NCT05673915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)
Description: Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.
Study NCT05673915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)
Description: Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.
Study NCT05302037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
Description: In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients.
Study NCT05900531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757
Description: administered orally
Study NCT05900531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and open-label sitagliptin
Description: both administered orally
Study NCT05900531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to K-757
Description: administered orally
Study NCT05900531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to K-757 and matching placebo to K-833
Description: both administered orally
Study NCT05900531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and K-833
Description: both administered orally
Study NCT05900531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to K-757, open-label sitagliptin
Description: both administered orally
Study NCT05526924 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: A combination of chemotherapy and radiation given at the same time to treat cancer.
Study NCT05526924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
Study NCT05526924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
Study NCT05526924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5FU)
Description: A chemotherapy drug used to treat different types of cancer.
Study NCT05526924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: An anti-cancer drug.
Study NCT06410547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LLM
Description: A LLM-based comparison between treatment and guideline will, if necessary, give treatment recommendations based on the guidline.
Study NCT06063291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID110521156
Description: subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
Study NCT06063291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of ID110521156
Description: subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
Study NCT06693336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMS001
Description: One time administration
Study NCT06694168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery
Description: The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.
Study NCT06694168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery
Description: The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.
Study NCT06694168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REGEND001 Autologous Therapy Product
Description: L-PRF is an autologous concentrate of platelet- and leukocyte-rich fibrin derived from blood, which through a centrifugation process allows to stimulate, improve and accelerate healing. The growth factors in the concentrates, together with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of the processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes and stem cells, L-PRF acts in immune regulation by controlling inflammation, with a continuous release of growth factors and presents an analgesic effect, which gives greater postoperative comfort to the patient. In addition, being an autologous product, it greatly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs and ease of preparation its use as a filling material in intraosseous defects will be evaluated.
Study NCT06701344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)
Description: Induction Treatment:~Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days
Study NCT06701344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: Maintenance Treatment:~Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT.
Study NCT06702280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IgY supplement
Description: Ingesting the immune supplement over the experimental period
Study NCT05191290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
Study NCT06700694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-assisted, family-engaged in-bed activities
Description: Technology-assisted, family-engaged in-bed activities include handgrip interactive games, virtual reality butterfly catching, virtual reality magic cube games, and immersive in-bed cycling, performed 20 minutes per session, twice daily, five days a week, primarily assisted by family members.
Study NCT06700694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol-oriented early mobilization program
Description: The protocol-oriented early mobilization program is implemented based on the patient's muscle strength and the Intensive care unit Mobility Scale (IMS), including lying, sitting, standing, stepping, and walking, once daily for 20-60 minutes, five days a week, carried out by physiotherapist and researcher.
Study NCT06700694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol-oriented early mobilization program
Description: The protocol-oriented early mobilization program is implemented based on the patient's muscle strength and the Intensive care unit Mobility Scale (IMS), including lying, sitting, standing, stepping, and walking, once daily for 20-60 minutes, five days a week, carried out by physiotherapist and researcher.
Study NCT05191290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Description: 8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
Study NCT05884437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Description: Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
Study NCT03865277 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose-escalated radiochemotherapy
Description: Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases > 2 cm.~Radiotherapy is always applied with 5 fractions per week.
Study NCT03865277 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose-escalated radiochemotherapy with carbon ion boost
Description: Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases > 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week.
Study NCT03865277 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: standard radiochemotherapy
Description: Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week.
Study NCT05144191 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Insignia uncemented Hip Stem
Description: Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
Study NCT05789407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry
Description: 1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
Study NCT05789407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry
Description: 1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
Study NCT05250362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28.
Study NCT06361576 — intervention group
Intervention type: DRUG
Intervention: Nivolumab
Description: As per product label
Study NCT04908488 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric contact lenses
Description: Soft contact lenses for optical correction of astigmatism
Study NCT04908488 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lenses
Description: Soft contact lenses for optical correction of astigmatism
Study NCT05057676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Autoimmune Intervention Mastery Course (AIM)
Description: Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
Study NCT05057676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Question and Answer sessions. (AIM Q and A sessions)
Description: Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
Study NCT05057676 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed Autoimmune Intervention Mastery Course (delayed AIM course)
Description: Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
Study NCT04810104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328
Description: Active study drug
Study NCT04810104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug
Study NCT05028283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Description: This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with atrophic acne scars on the cheeks
Study NCT05057676 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed AIM Question and Answer sessions
Description: Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
Study NCT06700720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 YN001
Description: Dose 1 YN001 will be administered on Day 1 and Day 5 of each week from Week 1 to Week 12, and on Day 1 of Week 13, 25 times in total.
Study NCT06700720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 YN001
Description: Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Study NCT06700720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
Study NCT05306067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LDH-based malaria rapid diagnostic test
Description: Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities